本文選題：Skp2蛋白 + Sp1蛋白　； 參考：《延邊大學》2017年碩士論文

【摘要】：目的:探討Skp2與Sp1在膀胱尿路上皮癌不同臨床分期、病理分級中的表達及兩者在同一膀胱癌組織中的相關(guān)性,以及與膀胱癌復(fù)發(fā)的關(guān)系。方法:選取延邊大學附屬醫(yī)院2012年1月-2015年12月間手術(shù)切除后確診為膀胱尿路上皮癌的病理標本69例,另選取20例癌旁非腫瘤膀胱粘膜組織供對照實驗。所選患者術(shù)前均未給予化療、放療及免疫治療。采用免疫組織化學PV-6000法檢測69例膀胱癌和20例癌旁非腫瘤膀胱粘膜組織中Skp2及Sp1蛋白表達,分析Skp2及Sp1在膀胱尿路上皮癌的不同臨床分期、病理分級中的表達及其臨床意義。結(jié)果:(1)Skp2在69例膀胱癌組以及20例癌旁非腫瘤膀胱粘膜組中陽性表達率為69.6%和10.0%,具有顯著性差異(P0.05)。Skp2在淺表型膀胱癌組和浸潤型膀胱癌組中陽性表達率為57.1%和88.9%,具有顯著性差異(P0.05)。Skp2在低分級膀胱癌組和高分級膀胱癌組中的陽性表達率為50.0%和80.0%,具有顯著性差異(P0.05)。Skp2在復(fù)發(fā)患者組和未復(fù)發(fā)患者組中陽性率為85.3%和54.3%,具有顯著性差異(P0.05)。(2)Sp1在69例膀胱癌組以及20例癌旁非腫瘤膀胱粘膜組中陽性表達率為81.2%和15.0%,具有顯著性差異(P0.05)。Sp1在淺表型膀胱癌組和浸潤型膀胱癌組中陽性表達率為71.4%和96.3%,具有顯著性差異(P0.05)。Sp1在低分級膀胱癌組和高分級膀胱癌組中的陽性表達率為58.3%和93.3%,具有顯著性差異(P0.05)。Sp1在復(fù)發(fā)患者組和未復(fù)發(fā)患者組中陽性率為91.2%和71.4%,具有顯著性差異(P0.05)。(3)Skp2與Sp1蛋白在同一膀胱癌組織中的表達呈正相關(guān)關(guān)系(P0.05)。結(jié)論:(1)Skp2和Sp1蛋白與膀胱癌的臨床分期和病理分級密切相關(guān),提示Skp2和Sp1可能參與了膀胱癌細胞增殖、浸潤、轉(zhuǎn)移和復(fù)發(fā)等過程。(2)Skp2與Sp1在膀胱癌組織中表達呈正相關(guān),推測Sp1可能通過激活Skp2從而促進了膀胱癌的發(fā)生和發(fā)展,聯(lián)合檢測Skp2與Sp1對評估膀胱癌的預(yù)后有一定的參考價值。
[Abstract]:Objective: to investigate the expression of Skp2 and Sp1 in different clinical stages and pathological grades of bladder urothelial carcinoma and their correlation with the recurrence of bladder cancer. Methods: 69 cases of bladder urothelial carcinoma confirmed by surgical resection from January 2012 to December 2015 in affiliated Hospital of Yanbian University were selected and 20 cases of non-cancerous bladder mucosa were selected for control experiment. All the patients were not given chemotherapy, radiotherapy and immunotherapy before operation. The expression of Skp2 and Sp1 in 69 cases of bladder cancer and 20 cases of non-cancerous bladder mucosa were detected by immunohistochemical PV-6000 method. The expression of Skp2 and Sp1 in different clinical stages, pathological grade and clinical significance of bladder urothelial carcinoma were analyzed. Results the positive expression rates of Skp2 in 69 cases of bladder cancer and 20 cases of non-cancerous bladder mucosa were 69.6% and 10.0, respectively. The positive expression rates of Skp2 in superficial bladder carcinoma and invasive bladder cancer were 57.1% and 88.9%, respectively. The positive rate of Skp2 in low grade bladder cancer group and high grade bladder cancer group was 50.0% and 80.0%, respectively. There was significant difference in the positive rate of P0.05N. Skp2 between relapsed patients and non-recurrence patients (85.3% and 54.3%, respectively). In 69 cases of bladder cancer and 20 cases of non-cancerous bladder mucosa adjacent to carcinoma, the positive expression rates were 81.2% and 15.0%, respectively. There was a significant difference in the positive expression rates of P0.05 and Sp1 in superficial bladder cancer and invasive bladder cancer. The positive rates were 71.4% and 96.3%, respectively. The positive expression rates of P0.05U. Sp1 in low grade bladder cancer group and high grade bladder cancer group were 58.3% and 93.3%, respectively. There was a significant difference in the positive rate of P0.05U 路Sp1 between relapsed patients and non-recurrence patients (91.2% and 71.4%, respectively). There was a significant difference between P0.05Skp2 and Sp1 eggs. The expression of white in the same bladder cancer was positively correlated with that of P0.05. Conclusion Skp2 and Sp1 proteins are closely related to the clinical stage and pathological grade of bladder cancer, suggesting that Skp2 and Sp1 may be involved in the process of proliferation, invasion, metastasis and recurrence of bladder cancer cells. The expression of Skp2 and Sp1 in bladder cancer tissues is positively correlated. It is speculated that Sp1 may promote the occurrence and development of bladder cancer by activating Skp2. The combined detection of Skp2 and Sp1 may be useful in evaluating the prognosis of bladder cancer.
【學位授予單位】：延邊大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R737.14

【參考文獻】

相關(guān)期刊論文 前10條

1 段松;;前列腺癌組織中Skp2的表達及其與前列腺癌術(shù)后復(fù)發(fā)的關(guān)系[J];東南國防醫(yī)藥;2016年01期

2 馬燕;趙雅淇;嚴美娟;趙建美;;P27~(kip1)、Jab1、Skp2在非霍奇金淋巴瘤中的表達及意義[J];實用醫(yī)學雜志;2015年24期

3 楊成成;南克俊;秦思達;;過表達人細胞S期激酶相關(guān)蛋白2(Skp2)促進MCF-7乳腺癌細胞生長及S期細胞增加[J];細胞與分子免疫學雜志;2015年10期

4 李勝;梅同華;;抑制skp2基因表達對肺癌移植瘤生長影響的實驗研究[J];臨床腫瘤學雜志;2015年10期

5 程維剛;李蕾蕾;劉九洲;殷德濤;郭萬里;;S期激酶相關(guān)蛋白2和細胞周期抑制蛋白p27kip1在乳腺癌組織中的表達及其臨床意義[J];中華實驗外科雜志;2015年10期

6 劉大闖;梁清;陶陶;黃燁清;許斌;陳恕求;張治國;董洋;韓從輝;陳明;;前列腺癌中Sp1通過PKM2途徑促進細胞增殖代謝[J];東南大學學報(醫(yī)學版);2015年03期

7 趙俊峰;肖耀軍;姜耀東;趙善超;楊旭凱;鄭少斌;;沉默G250基因?qū)δI癌786-0細胞移植瘤Skp2表達的影響[J];中國老年學雜志;2015年01期

8 趙靜;吳娟;楊麗娜;李郁;張芳琳;楊紅;;Sp1調(diào)控FoxM1在卵巢癌中的表達[J];科學技術(shù)與工程;2014年28期

9 張連峰;魏爭;韓利坤;張緒文;喬海泉;;RNAi沉默Skp2抑制胃癌細胞SGC7901侵襲作用的實驗研究[J];醫(yī)學綜述;2014年12期

10 靳文劍;張q和;陳火國;羅慶豐;;β-Catenin、Skp~2和p~(27)在老年肝細胞癌中的表達及相關(guān)性[J];中國老年學雜志;2014年05期

，

本文編號：1840238